

NOS3 Antibody (N-term) Blocking Peptide
Synthetic peptide
Catalog # BP6963a**Specification****NOS3 Antibody (N-term) Blocking Peptide -
Product Information**Primary Accession [P29474](#)**NOS3 Antibody (N-term) Blocking Peptide -
Additional Information****Gene ID** 4846**Other Names**Nitric oxide synthase, endothelial,
Constitutive NOS, cNOS, EC-NOS,
Endothelial NOS, eNOS, NOS type III, NOSIII,
NOS3**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP6963a](/products/AP6963a) was selected from the N-term region of human NOS3. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**NOS3 Antibody (N-term) Blocking Peptide -
Protein Information****Name** NOS3**NOS3 Antibody (N-term) Blocking Peptide
- Background**

Nitric oxide is a reactive free radical which acts as a biologic mediator in several processes, including neurotransmission and antimicrobial and antitumoral activities. Nitric oxide is synthesized from L-arginine by nitric oxide synthases.

**NOS3 Antibody (N-term) Blocking Peptide
- References**

Rikova, K., et.al., Cell 131 (6), 1190-1203 (2007)

Function

Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the activation of platelets.

Cellular Location

Cell membrane. Membrane, caveola. Cytoplasm, cytoskeleton. Golgi apparatus. Note=Specifically associates with actin cytoskeleton in the G2 phase of the cell cycle; which is favored by interaction with NOSIP and results in a reduced enzymatic activity

Tissue Location

Platelets, placenta, liver and kidney.

**NOS3 Antibody (N-term) Blocking Peptide
- Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)